PresentationsA Rapid Matrix Approach for the Discovery of Potent IRAK4 Targeted Protein Degraders By webmaster / August 21, 2024
PresentationsLatest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies By webmaster / June 16, 2024
PresentationsAutomated Method Development for High Throughput Purification at Nurix Therapeutics By AldenMC Production / May 28, 2024
PresentationsInitial finding from a first-in-human Phase 1a/b trial of NX-5948, a selective BTK degrader By AldenMC Production / April 28, 2024
PresentationsInitial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / April 19, 2024
PresentationsNX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma By AldenMC Production / April 9, 2024
PresentationsTargeting Degraders to the CNS for the Treatment of Cancer By AldenMC Production / April 5, 2024
PresentationsInitial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies By AldenMC Production / April 3, 2024
PresentationsApproaches for DNA-Encoded Library Screening of Transcription Factors By AldenMC Production / April 2, 2024
